Core Insights - The U.S. Environmental Protection Agency (EPA) has proposed the registration decision for Biotalys' first biofungicide, EVOCA, initiating a public participation procedure for stakeholder feedback [1][4] - EVOCA's active ingredient residues on treated crops are exempt from tolerance requirements, indicating no maximum residue limits will apply, which emphasizes the product's safety profile [2] - EVOCA targets fungal pathogens like botrytis and powdery mildew in high-value fruits and vegetables, offering a new mode of action to manage resistance to existing fungicides [3][8] Company Developments - The EPA's recommendation to approve EVOCA is a significant milestone for Biotalys, marking the advancement of the first protein-based biofungicide for approval in the U.S. [4] - Biotalys' protein-based platform aims to transform crop protection by delivering next-generation biological solutions tailored to farmers' needs [5] - The approval of EVOCA sets the stage for the regulatory submission of EVOCA NG, a next-generation version, which is expected to have a shorter review process due to its similar active ingredient [6] Industry Context - Biotalys is positioned as a leader in agricultural innovation, with a focus on developing precision biocontrol solutions based on proteins for crop protection [9][10] - The company was founded in 2013 as a spin-off from the VIB (Flanders Institute for Biotechnology) and is listed on Euronext Brussels, operating within a biotech cluster in Ghent, Belgium [10]